Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet a light for pathogen inactivation: The SPRINT trial

Edward Snyder, Jeffrey McCullough, Sherrill J. Slichter, Ronald G. Strauss, Ileana Lopez-Plaza, Jin Sying Lin, Laurence Corash, Maureen G. Conlan

Research output: Contribution to journalArticle

103 Scopus citations

Abstract

BACKGROUND: A photochemical treatment (PCT) method utilizing a novel psoralen, amotosalen HCl, with ultraviolet A illumination has been developed to inactivate viruses, bacteria, protozoa, and white blood cells in platelet (PLT) concentrates. A randomized, controlled, double-blind, Phase III trial (SPRINT) evaluated hemostatic efficacy and safety of PCT apheresis PLTs compared to untreated conventional (control) apheresis PLTs in 645 thrombocytopenic oncology patients requiring PLT transfusion support. Hemostatic equivalency was demonstrated. The proportion of patients with Grade 2 bleeding was not inferior for PCT PLTs. STUDY DESIGN AND METHODS: To further assess the safety of PCT PLTs, the adverse event (AE) profile of PCT PLTs transfused in the SPRINT trial is reported. Safety assessments included transfusion reactions, AEs, and deaths in patients treated with PCT or control PLTs in the SPRINT trial. RESULTS: A total of 4719 study PLT transfusions were given (2678 PCT and 2041 control). Transfusion reactions were significantly fewer following transfusion of PCT than control PLTs (3.0% vs. 4.1%; p = 0.02). Overall AEs (99.7% PCT vs. 98.2% control), Grade 3 or 4 AEs (79% PCT vs. 79% control), thrombotic AEs (3.8% PCT vs. 3.7% control), and deaths (3.5% PCT vs. 5.2% control) were comparable between treatment groups. Minor hemorrhagic AEs (petechiae [39% PCT vs. 29% control; p < 0.01] and fecal occult blood [33% PCT vs. 25% control; p = 0.03]) and skin rashes (56% PCT vs. 42% control; p < 0.001) were significantly more frequent in the PCT group. CONCLUSION: The overall safety profile of PCT PLTs was comparable to untreated PLTs.

Original languageEnglish (US)
Pages (from-to)1864-1875
Number of pages12
JournalTransfusion
Volume45
Issue number12
DOIs
StatePublished - Dec 1 2005

Fingerprint Dive into the research topics of 'Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet a light for pathogen inactivation: The SPRINT trial'. Together they form a unique fingerprint.

  • Cite this

    Snyder, E., McCullough, J., Slichter, S. J., Strauss, R. G., Lopez-Plaza, I., Lin, J. S., Corash, L., & Conlan, M. G. (2005). Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet a light for pathogen inactivation: The SPRINT trial. Transfusion, 45(12), 1864-1875. https://doi.org/10.1111/j.1537-2995.2005.00639.x